60855RAC4

• GAAP net income was $60 million ($1.19 per diluted share) versus $255 million ($4.75) in Q2 2025; adjusted net income was $77 million ($1.51) versus $294 million ($5.48).
• Consolidated medical care ratio (MCR) was 92.2% in Q2 2026, up from 90.4% a year ago; Medicaid MCR was 92.7%, Medicare 90.7%, Marketplace 88.9%.
• Full-year 2026 guidance raised: GAAP EPS to at least $2.15 and adjusted EPS to at least $5.25 (up $0.25); premium revenue guidance unchanged at ~$42 billion.
• Operating cash flow for H1 2026 was $788 million, versus an outflow of $112 million in H1 2025; membership was ~4.9 million as of June 30, 2026.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Illinois HFS intends to award a HealthChoice Illinois Medicaid Managed Care contract to Molina Healthcare of Illinois.
• Molina Healthcare of Illinois will be one of six health plans serving Illinois's roughly 3.1 million Medicaid beneficiaries.
• The announcement was made via press release on June 10, 2026, and filed under Regulation FD Disclosure.
• The award is subject to risks including protest or legal action, delay in start date, or shorter contract term.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing authorized shares by 1,500,000 to 3,295,000.
• The Board adopted amended and restated Bylaws effective May 6, 2026, implementing special meeting procedures and requirements.
• All ten director nominees were elected at the May 6, 2026 Annual Meeting; all five proposals passed.
• The say-on-pay proposal passed with 22,459,321 votes for and 20,116,888 against.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• The company provided updates on long-term financial targets, strategic and operational plans, including 2029 performance outlook, premium revenue, and adjusted EPS targets.
• The presentation materials were attached as Exhibit 99.1 to the Form 8-K.
• A live webcast and 30-day replay are available on the company's investor relations website.
• The disclosure was made under Regulation FD to provide public access to the Investor Day materials.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP net income was $14 million ($0.27 per diluted share), down from $298 million ($5.45 per diluted share) in Q1 2025, reflecting a $93 million impairment related to the planned exit of the Medicare Advantage-Part D product for 2027.
• Adjusted net income was $120 million ($2.35 per diluted share), down from $333 million ($6.08 per diluted share) in Q1 2025.
• Consolidated medical care ratio (MCR) was 91.1% in Q1 2026, up from 89.2% in Q1 2025; G&A ratio was 7.2% (6.9% adjusted).
• The company reaffirmed full-year 2026 guidance of premium revenue of approximately $42 billion and adjusted earnings of at least $5.00 per diluted share.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Molina Healthcare will reaffirm its 2026 full-year GAAP diluted EPS guidance of at least $3.20 and adjusted diluted EPS guidance of at least $5.00 at investor meetings and the TD Cowen conference on March 3, 2026.
• Molina will release Q1 2026 earnings after market close on April 22, 2026, and host a conference call on April 23, 2026 at 8:00 a.m. ET.
• Molina will host its 2026 Investor Day on May 8, 2026 at 9:30 a.m. ET, with a live webcast and 30-day replay available online.
• The disclosure is made under Regulation FD, and the information is not deemed 'filed' for SEC purposes.

7.01 Regulation FD Disclosure

• The company will record an estimated non-cash, pre-tax impairment charge of approximately $93 million in Q1 2026, related to intangible assets.
• The impairment stems from the decision to exit the Medicare Advantage Prescription Drug product for 2027, focusing instead on dual eligible members in Medicare.
• The impairment charge will be recorded outside of adjusted net income, as defined in the Q4 earnings release issued February 5, 2026.
• The Amended Credit Agreement is filed as Exhibit 10.1 to the Form 8-K.

1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 2.06 Material Impairments · 9.01 Financial Statements and Exhibits

• Full-year 2025 GAAP earnings per diluted share were $8.92, and adjusted earnings per diluted share were $11.03, both down significantly year over year.
• Full-year 2025 premium revenue was approximately $43.1 billion, up 11% year over year, reflecting acquisitions, rate increases, and organic growth.
• The company issued 2026 guidance: premium revenue of approximately $42 billion, GAAP EPS of at least $3.20, and adjusted EPS of at least $5.00, burdened by $2.50 per share from a new Florida Medicaid contract and MAPD underperformance.
• Operating cash flow for 2025 was an outflow of $535 million, compared to an inflow of $644 million in 2024, driven by Medicaid risk corridor settlements and lower operating performance.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits